clinical trial · NCT07589686
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
Obesity or OverweightPetrelintideEnicepatidePetrelintide-matching PlaceboEnicepatide-matching Placebo
brief summary
The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related comorbidity.
started
Jun 30, 2026
primary completion
Nov 12, 2027
completion
Jan 31, 2028
last updated
Jun 12, 2026
official title
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy and Safety of Petrelintide Co-Administered With RO7795068 in Adults With Obesity or Overweight
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol